In parallel to the manufacturing and distribution activities of bone allografts, TBF is heavily investing in biotechnology innovation upon processes to bring new therapies to practitioners:
- PHOENIX demineralized bone allograft, DBM from cortical bone of living donor, which also undergo a thorough securing process. A phase II clinical trial is intended for indications requiring the combination of two important properties of bone: osseoconduction and osteoinduction.
- MENISC-T, meniscal allografts from the knee arthroplasty. The latter undergo a securing treatment comparable to PHOENIX bone allografts.